Can-Fite up on compassionate use nod for cancer drug in Romania

Can Fite Biopharma

23/08/2022 13:12

** U.S.-listed shares of Israeli biotech co Can-Fite
BioPharma  CANF.N  rise 13.6% to $1.00 premarket
    ** Co says its experimental drug candidate has been approved
for compassionate use in Romania for treatment of advanced liver
cancer  urn:newsml:reuters.com:*:nBw407rtca
    ** The drug, Namodenoson, was previously approved for
compassionate use in Israel
    ** CANF says late-stage study of Namodenoson for treating
advanced liver cancer is open for recruitment and will recruit
patients from Israel, U.S., and five countries in Europe
    ** U.S. stock was down ~31% YTD as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))